CClinicalTrials.gg
Status unknownNCT05597384ABILITYUpdated Mar 8, 2023

Assessment of Autologous Blood Marker Localization in Laparoscopic Colorectal Cancer Surgery

An interventional study of Laparoscopic colorectal cancer resection in Colorectal Cancer, sponsored by Shanghai East Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-08.

Sponsored by Shanghai East Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Laparoscopic colorectal surgery has been proved to have similar oncological outcomes with open surgery. Due to the lack of tactile perception, surgeons may have misjudgments in laparoscopic colorectal surgery. Therefore, the accurate localization of a tumor before surgery is important, especially in the early stages of cancer. Recently, some retrospective studies reported the use of patients' autologous blood for preoperative colonic localization in colorectal cancer with successful detection by laparoscopy, but its benefits remain controversial. This study aimed to assess the accuracy and safety of autogenous blood marker localization in laparoscopic radical resection for colorectal cancer.

Read the detailed description

Laparoscopic surgery has become the standard for management of colorectal cancer(CRC) with the advantages of less traumatic procedure, but similar oncological outcomes to open surgery. Due to the lack of tactile perception (haptic feedback), surgeons may have misjudgments in patients with small or flat early colon cancer, malignant polyps resected by endoscopic mucosal resection or endoscopic submucosal dissection. Therefore, the accurate localization of a tumor before surgery is important, especially in the early stages of cancer, to clarify the extent of surgical resection.

Several methods are currently being proposed and used to identify the location of tumors. These include endoscopic tattooing with India ink, indocyanine green (ICG), preoperative endoscopic metal clipping with detection using an x-ray or palpation during surgery, and intraoperative endoscopy.

Recently, some retrospective studies reported the use of patients' autologous blood for preoperative colonic localization in CRC with successful detection by laparoscopy. Autologous blood was thought a feasible and safe tattooing agent for preoperative endoscopic localization. Nonetheless, all currently available evidence comes from observational studies that are susceptible to bias. We therefore proposed to conduct this randomized controlled clinical trial to evaluate the accuracy and safety of autogenous blood marker localization in laparoscopic radical resection for colorectal cancer.

02

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal cancer
  • Autologous blood
  • Endoscopy tattooing
  • Preoperative localization
03

In context

Colorectal Neoplasms

5,600 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's planned enrollment of 220 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Shanghai East Hospital is the lead sponsor of 92 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age from 18 to 80 years
  2. Large lateral spreading tumors that could not be treated endoscopically, serosa-negative malignant colorectal tumors (≤ cT3), and malignant polyps treated endoscopically that required additional colorectal resection.
  3. The tumor is located in the colon, middle and high rectum (the lower margin of the tumor does not exceed peritoneal reflexes)
  4. No distant metastasis.
  5. American Society of Anesthesiology score (ASA) class I-III
  6. Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)
  7. Written informed consent

Exclusion criteria

Exclusion Criteria:

  1. BMI > 35kg/m2
  2. Previous history of gastrointestinal surgery that altered the gastrointestinal anatomy.
  3. Pregnant or lactating women
  4. Severe mental disorder
  5. History of previous abdominal surgery (except cholecystectomy and appendectomy) Rejection of laparoscopic resection
  6. History of cerebrovascular accident within the past six months
  7. History of unstable angina or myocardial infarction within the past six months
  8. History of previous neoadjuvant chemotherapy or radiotherapy
  9. Comorbidity of emergent conditions like obstruction, bleeding or perforation.
  10. Needing simultaneous surgery for other diseases.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Autologous Blood Marker Group

    The tattooing was performed at 24-48 hours before the surgery. When the lesion was identified by endoscopy, 2-3 ml of the patient's peripheral venous blood without heparin preparation were injected submucosally at the distal side and proximal side of the lesion using a conventional endoscopic needle without submucosal injection of normal saline.

    Procedure: Laparoscopic colorectal cancer resection

  • Active comparator
    Intraoperative colonoscopy group

    Under general anesthesia with endotracheal intubation, the patient was placed in the modified lithotomy position. After routine laparoscopic exploration, CO2-insufflated intraoperative colonoscopy was performed using a flexible videocolonoscope. Upstream small bowel clamping was applied before intraoperative colonoscopy. During intraoperative colonoscopy, CO2 pneumoperitoneum was maintained by the insufflator so that the laparoscope could guide the colonoscope effectively.

    Procedure: Laparoscopic colorectal cancer resection

Interventions

  • ProcedureLaparoscopic colorectal cancer resection

    This is one of the routine procedures used for colorectal cancer resection.

06

What researchers measure

Primary outcomes

  1. Autogenous blood marker localization was not inferior to intraoperative colonoscopy localization

    While checking the intraperitoneal cavity at the start of the surgery, the visibility of tattooing will be first checked. After the complete resection of the colon segment, resected colon specimen will be checked the localization with autologous blood tattooing. The localization accuracy of autologous blood marker will be similar to that of intraoperative colonoscopy localization.

    Time frame: From the beginning of endoscopic tattooing to the end of the surgery.

Secondary outcomes

  1. Adverse events related to endoscopic tattooing

    The secondary endpoint is the localization safety. Adverse events related to endoscopic tattooing, such as perforation, abscess formation, peritonitis, post-tattoo fever, post-tattoo abdominal pain, and intraperitoneal spillage of tattooing agent, were evaluated in autologous blood group.

    Time frame: From the beginning of colonoscopic tattooing to 2 weeks after surgery.

07

Study locations

1 of 1 sites recruiting
  • Shanghai East Hospital
    Shanghai, Shanghai 200123, China
    • Xiaohua Jiang, MD · Contact
    • Shun Zhang, MD · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05597384
Lead sponsor
Shanghai East Hospital
Responsible party
Sponsor
First posted
Oct 28, 2022
Start date
Nov 1, 2022
Primary completion
Apr 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Mar 8, 2023

Study contacts

Xiao-hua Jiang, MD
Contact
jiangxiaohuash@163.com
(8621)38804518
Shun Zhang, MD
Contact
v2zs@hotmail.com
(8621)38804518

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion